[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Guangdong Women and Children Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":70},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,40],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100636854","construction-of-a-multi-dimensional-risk-assessment-system-a-clinical-study-of-polycystic-ovary-syndrome-complicated-with-thrombophilia-100636854",false,"NCT07571096","Construction of a Multi-dimensional Risk Assessment System: a Clinical Study of Polycystic Ovary Syndrome Complicated With Thrombophilia","Inclusion Criteria:\n\n* Female participants aged 14 to 45 years\n* Diagnosis of polycystic ovary syndrome (PCOS)\n* For adult participants, PCOS diagnosed according to the 2023 international evidence-based guideline. After exclusion of related disorders, diagnosis is based on ovulatory dysfunction and\u002For irregular menstrual cycles together with clinical hyperandrogenism, biochemical hyperandrogenism, or polycystic ovarian morphology on ultrasound where appropriate\n* For adolescent participants, PCOS diagnosed according to adolescent-specific recommendations. After exclusion of related disorders, both ovulatory dysfunction and\u002For irregular menstrual cycles and clinical or biochemical hyperandrogenism are required\n* Irregular menstrual cycles are defined as follows: more than 1 year and less than 3 years after menarche, menstrual cycles shorter than 21 days or longer than 45 days; more than 3 years after menarche to perimenopause, menstrual cycles shorter than 21 days or longer than 35 days, or fewer than 8 cycles per year; any cycle longer than 90 days more than 1 year after menarche; or primary amenorrhea by age 15 years or more than 3 years after thelarche\n* No use within 3 months before blood sampling of anticoagulant drugs, procoagulant drugs, oral contraceptives, or other medications that may affect sex hormones, insulin, glucose metabolism, or coagulation function\n\nExclusion Criteria:\n\n* Confirmed pregnancy\n* Hematologic disease\n* History of malignant tumor\n* Use of medications within 12 weeks before enrollment that may interfere with study assessments\n* Disorders that may cause hyperandrogenism or ovulatory dysfunction, including congenital adrenal hyperplasia, Cushing syndrome, functional hypothalamic amenorrhea, thyroid disease, hyperprolactinemia, or primary ovarian insufficiency\n* Disorders that may affect protein C or protein S levels, including antiphospholipid syndrome, liver disease, or tumor-related conditions\n* In adolescents, polycystic ovarian morphology alone will not be used to establish the diagnosis of PCOS","FEMALE","14 Years","45 Years",{"count":19,"type":20},100,"ESTIMATED","1 Day","OBSERVATIONAL","This observational case-control study aims to develop a multidimensional risk assessment model for thrombophilia-related abnormalities in females with polycystic ovary syndrome (PCOS). The study will analyze endocrine, metabolic, and genetic factors associated with decreased protein C and\u002For protein S levels in participants with PCOS. The results are expected to provide evidence for risk stratification and individualized management in this population.",[25,26],"Polycystic Ovary Syndrome (PCOS)","Thrombophilia","RECRUITING","2026-07-29",{"date":30,"type":31},"2026-07-30","ACTUAL",{"date":33,"type":31},"2025-03-04",{"date":35,"type":20},"2027-03-17",{"name":37,"class":38},"Guangdong Women and Children Hospital","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":15,"minAge":47,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":51,"conditions":52,"keywords":55,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":39},"100645671","clinical-efficacy-and-safety-of-dydrogesterone-in-the-treatment-of-abnormal-uterine-bleeding-during-puberty-100645671","NCT07703488","Clinical Efficacy And Safety of Dydrogesterone In The Treatment Of Abnormal Uterine Bleeding During Puberty","Clinical Efficacy and Quality of Life Assessment of Dydrogesterone in Managing Abnormal Uterine Bleeding of Ovulatory Disorders in Adolescents：A Multicenter Prospective Cohort Study","Inclusion Criteria:\n\n* Female patient between 10-19 years old, already experiencing menarche and at least 6 months away from menarche\n* According with the criteria of Abnormal Uterine Bleeding of Ovulatory Disorders: irregular menstrual cycles (cycle interval\\\u003C21 days or\\>45 days, or adjacent menstrual intervals\\>90 days), prolonged menstrual periods (\\>7 days), excessive menstrual flow, poor bleeding control (score\\>100 on the menstrual bleeding assessment scale, or a significant increase in the frequency of changing hygiene products) within the past 3 months, and has ruled out pregnancy related and obvious structural causes.\n* The guardian of the subject signs the informed consent and obtains the consent of the subject.\n* With complete baseline clinical data: complete blood count, serum ferritin, Six types of sex hormones(FSH, LH, E2, P, T, PRL), Gynecological Sonography.\n\nExclusion Criteria:\n\n* Coagulation disorder\n* Requiring long-term anticoagulant and antiplatelet therapy\n* Secondary Abnormal Uterine Bleeding caused by uncontrolled hyperthyroidism, hypothyroidism, hyperprolactinemia, or other endocrine diseases.\n* Dysfunction of kidney and liver, or a history of severe intolerance or allergy to dydrogesterone, medroxyprogesterone, or other progestogens.","10 Years","19 Years",{"count":50,"type":20},240,"This multicenter prospective cohort study evaluates the clinical efficacy and safety of dydrogesterone versus drospirenone and ethinylestradiol in adolescents aged 10-19 years with abnormal uterine bleeding-ovulatory dysfunction (AUB-O). Patients who meet the FIGO PALM-COEIN criteria for AUB-O, have complete baseline clinical data, and provide guardian consent with adolescent assent are enrolled. Participants are allocated to receive either dydrogesterone or drospirenone and ethinylestradiol according to routine clinical practice. The primary outcome is the 6-month menstrual normalization rate (cycle length 21-35 days). Secondary outcomes include breakthrough bleeding, recurrence, adverse events, and quality-of-life improvements. Follow-up is conducted during treatment and for 6 months after treatment cessation, during which menstrual normalization is evaluated based on changes in menstrual cycle patterns and examination findings. The findings may help clarify the comparative effectiveness and safety of these two hormonal regimens for long-term cycle management in adolescents with AUB-O.",[53,54],"Abnormal Uterine Bleeding (AUB)","Ovulation Dysfunction",[56,57,58,59,60,61],"Abnormal Uterine Bleeding","Ovulation dysfunction type","Dydrogesterone","Drospirenone And Ethinylestradioare","Adolescence","Prospective Cohort","2026-07-08",{"date":64,"type":31},"2026-07-14",{"date":66,"type":31},"2026-07-06",{"date":68,"type":20},"2028-07-28",{"name":37,"class":38},""]